Benitec Biopharma ROA 2014-2022 | BNTC
Current and historical return on assets (ROA) values for Benitec Biopharma (BNTC) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Benitec Biopharma ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-09-30 |
$-0.02B |
$0.02B |
-150.00% |
| 2022-06-30 |
$-0.02B |
$0.01B |
-150.00% |
| 2022-03-31 |
$-0.02B |
$0.01B |
-107.94% |
| 2021-12-31 |
$-0.02B |
$0.01B |
-109.09% |
| 2021-09-30 |
$-0.02B |
$0.02B |
-94.12% |
| 2021-06-30 |
$-0.01B |
$0.02B |
-94.92% |
| 2021-03-31 |
$-0.01B |
$0.01B |
-104.00% |
| 2020-12-31 |
$-0.01B |
$0.02B |
-118.92% |
| 2020-06-30 |
$-0.01B |
$0.01B |
-85.71% |
| 2020-03-31 |
$-0.01B |
$0.00B |
-62.50% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
